



2015 HIGHLIGHTS

- Our pipeline remained robust, with over 300 proposals considered
- Our portfolio companies raised an aggregate \$75M in co-investments, follow-on financing, and grants
- CardiAQ Valve Technologies, Broadview's first investment, was acquired by Edwards Lifesciences for \$400M, taking CardiAQ's disruptive mitral valve technology one step closer to patients
- Broadview hosted its inaugural Annual Meeting, bringing together all 24 of its active portfolio companies with leaders in venture capital, industry and academia
- We further expanded our team with the addition of Nishant Rastogi as an Associate

OUR PORTFOLIO COMPANIES


Broadview Ventures made 3 new investments in 2015:

- Pulmokine—small molecule PDGFR agonists for the treatment of pulmonary artery hypertension
- 480 Biomedical—self-expanding, bioresorbable stent for treatment of superficial femoral artery disease and pediatric cardiovascular indications
- Cardero Therapeutics—mitochondrial biogenesis for treatment of muscular dystrophy and related disorders

We were fortunate to co-invest with Polaris Ventures, Northbridge Venture Partners, Medtronic, and MRL Ventures, among others.

Our portfolio companies reached many important milestones:

- GI Windows—completed a first-in-human (FIH) trial testing its minimally invasive approach to gastric bypass in 10 patients
- Vascular Graft Solutions—received an IDE to proceed directly to a pivotal trial in the US; continued strong commercial uptake trend in the EU
- Zumbro—successfully completed 25 patient Phase 1b trial in resistant-like hypertensive patients
- Cardialen—completed a 40-patient FIH trial of its AF cardioversion therapy
- Remedy—completed an 80 patient Phase 2 trial of its stroke treatment, showing significant reduction in mortality



BROADVIEW'S INVESTMENTS ARE LEVERAGED 8X BY CO-AND FOLLOW-ON INVESTMENTS, AND NON-DILUTIVE GRANT FUNDING

OUR MISSION

In 2008, the Leducq Family Trust established Broadview Ventures with the mission to accelerate the development of promising technology in cardiovascular and neurovascular disease through targeted investments in and support of early stage ventures.

By making funding available at a critical moment in the development of new technology, the Leducq Family Trust is taking a leadership position in venture philanthropy by finding creative ways to support translational research in order to bring the advancements of science to the care of patients.

Portfolio Through 2015

	Company	Technology/Therapy	Founders/Management
2009	CardiAQ Valve*	<i>transcatheter mitral valve</i>	Brent Ratz/Arshad Quadri/Rob Michiels
	VentriNova	<i>gene therapy for regeneration of cardiac tissue</i>	Hina Chaudhry
	miRagen	<i>microRNA's for cardiovascular diseases</i>	Bruce Booth/Mike Bristow/Eric Olson
2010	Allosteros	<i>CaMKII inhibitors for HF and AF</i>	Howard Schulman/Mark Anderson
	Intravascular Imaging	<i>NIRF device for intracoronary artery imaging</i>	Farouc Jaffer/Vasilis Ntziachristos
	Capricor* CellAegis	<i>allogeneic stem cell therapy after MI remote ischemic conditioning for MI</i>	Eduardo and Linda Marbán Andrew Redington/Chris Calderone/Rocky Ganske
2011	Cardialen	<i>implantable pain-free cardioversion for the treatment of AF</i>	Igor Efimov/Paula Skjefte
	NuPulse	<i>minimally invasive medical device to treat HF</i>	Valluvan Jeevanandam/Douglas Altschuler
	Aggamin	<i>novel preeclampsia treatment</i>	Ravi Thadhani/Paul Kussie/Ananth Kamuranchi
	Provasculon* Apama	<i>peptide therapeutics for treatment of MI and I/R injury novel ablation system for treatment of AF</i>	Rich Lee/Roger Kitterman Amr Salahieh
2012	VGS	<i>external support for saphenous vein grafts in CABG</i>	Eyal Orion/Yanai Ben Gal
	InfoBionic	<i>cloud-based remote arrhythmia monitoring</i>	Nancy Briefs
	Herantis	<i>VEGF based gene therapy for lymphedema</i>	Pekka Simula/Burkhard Blank
	Declimmune	<i>MAB for treatment of post MI and I/R injury</i>	Michael Carroll/Francis Moore
2013	Zumbro Discovery	<i>peptide therapeutic for treatment of resistant hypertension</i>	John Burnett/Horng Chen
	BioKier	<i>medicinalization of anti-diabetic effects of bariatric surgery</i>	George Szewczyk/Roger Nolan
	Remedy	<i>small molecule for the treatment of stroke</i>	Sven Jacobson
	GI Windows	<i>non-surgical approach to gastric bypass</i>	Chris Thompson/Marvin Ryou/James Wright
2014	ZZ Biotech	<i>peptide therapeutic for stroke</i>	Berislav Zlokovic/Kent Pryor
	Ischemia Care	<i>gene-based diagnostic for stroke</i>	Jeff June
	Acesion Pharma	<i>small molecule therapeutic for AF</i>	Ulrik Sørensen/Morten Grunnet
	Aria CV	<i>device for pulmonary artery hypertension</i>	John Scandurra/Karl Vollmers
2015	Pulmokine	<i>small molecule for pulmonary artery hypertension</i>	Larry Zisman/Shreefal Mehta
	480 Biomedical	<i>bioresorbable stent for multiple indications</i>	Bob Langer/George Whitesides/Maria Palasis
	Cardero Therapeutics	<i>mitochondrial biogenesis platform technology</i>	George Schreiner/Sundeep Dugar

* Exited

MANAGEMENT

Christopher Colecchi
Managing Director

Maria Berkman
Christopher de Souza
Rick Jones
Nishant Rastogi
Nichole Schiffer

ADVISORS

Annabel Chen-Tournoux
Teo Dagi
Marc Semigran

STRATEGIC

ADVISORY BOARD

Eugene Braunwald
Kim Fox
Thomas Hughes
Jerry Karabelas
Martín Landaluze
Joseph Loscalzo
Eric Rose
David Tancredi

BROADVIEW'S INVESTMENT BY INDICATION

